COVID-19 Vaccine Skycovion Among Raft Of New EU Filings
Executive Summary
EU marketing authorization applications for 12 products, including Skycovion, trastuzumab duocarmazine, alpelisib and sparsenta, are now being evaluated by the European Medicines Agency.
You may also be interested in...
New EU Filings
Danicopan, from AstraZeneca, for the treatment of extravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria, is among the latest drugs that have been filed for review by the European Medicines Agency for potential EU marketing approval.
New EU Filings
Sugemalimab, from CStone Pharmaceuticals/EQRx, for use in combination with chemotherapy as first-line treatment for metastatic non-small cell lung cancer, is among the latest drugs that have been filed for review by the European Medicines Agency for potential EU marketing approval.
New EU Filings
Aprocitentan, Idorsia/Janssen Biotech’s investigational, novel dual endothelin receptor antagonist, for the treatment of patients with resistant hypertension, is among the latest drugs that have been filed for review by the European Medicines Agency for potential EU marketing approval.